Unusually active option classes on open April 20th » 09:4004/2004/20/21
FSR, CLNE, MO, SNDL, CZR, CLOV, ABT, MVIS, MPC, PG
Unusual total active…
Unusual total active option classes on open include: Fisker (FSR), Clean Energy (CLNE), Altria Group (MO), Sundial Growers (SNDL), Caesars (CZR), Clover Health (CLOV), Abbott (ABT), Microvision (MVIS), Marathon Petroleum (MPC), and Procter & Gamble (PG).
Clover Health appoints Demetrios Kouzakas to board of directors » 09:2904/1504/15/21
Clover Health Investments…
Clover Health Investments announced Demetrios Kouzakas has joined its Board of Directors and will serve as a member of the Audit Committee. For the last four years, until January 2021, Demetrios Kouzoukas served as the Director of the Center for Medicare and the Principal Deputy Administrator of the Centers for Medicare & Medicaid Services.
|Over a week ago|
Unusually active option classes on open April 9th » 09:4004/0904/09/21
FUBO, CLOV, ASO, ET, SHOP, ETSY, MT, EMB, JPM, GS
Unusual total active…
Unusual total active option classes on open include: fuboTV (FUBO), Clover Health (CLOV), Academy Sports and Outdoors (ASO), Energy Transfer (ET), Shopify (SHOP), Etsy (ETSY), ArcelorMittal (MT), iShares Emerging Markets Bond ETF (EMB), JPMorgan (JPM), and Goldman Sachs (GS).
Clover Health call buyer realizes 490% same-day gains » 08:0004/0904/09/21
Notable profits for the…
Notable profits for the buyer who lifted the $0.25 offer for 3,349 Clover Health (CLOV) Apr-21 7.5 calls yesterday at 14:09ET when underlying shares were trading at $7.24. Shares closed at $8.85, and the calls at $1.48 for a mark-to-market profit of 490%, or $410K, on the $84K outlay.
Clover Health call volume above normal and directionally bullish » 14:4504/0804/08/21
Bullish option flow…
Bullish option flow detected in Clover Health with 97,908 calls trading, 6x expected, and implied vol increasing almost 47 points to 121.71%. May-21 10 calls and Apr-21 10 calls are the most active options, with total volume in those strikes near 50,000 contracts. The Put/Call Ratio is 0.09. Earnings are expected on May 3rd.
Clover Health listed by CMS among DCEs participating in PY21 GPDC model » 14:4304/0804/08/21
The Center for Medicare…
The Center for Medicare and Medicaid Innovation announced that 53 Direct Contracting Entities, or DCEs, are participating in Performance Year 2021 of the Global and Professional Direct Contracting, or GPDC, Model, which starts April 1, 2021. "The DCEs will serve Medicare fee for service beneficiaries in 38 states as well as in the District of Columbia and Puerto Rico. 39 of these DCEs have selected the Global risk sharing option and 14 have selected the Professional risk sharing option. These 53 DCEs include multiple DCE types with 31 Standard DCEs, 16 New Entrant DCEs, and 6 High Needs Populations DCEs," the CMS notice stated. Clover Health is listed by the CMS as a "Standard" DCE Type for the states of Arizona, Georgia, Kansas, New Jersey, New York, Pennsylvania, Rhode Island, South Carolina, Texas and Vermont. In afternoon trading, Clover Health shares are up $1.12, or 15%, to $8.47. Reference Link
Largest borrow rate increases among liquid names » 08:4503/2203/22/21
EARS, INMD, NBRV, GPL, ARKF, PSTI, APPH, NMM, CLOV
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Auris Medical (EARS) 56.73% +0.83, InMode (INMD) 3.91% +0.83, Nabriva Therapeutics (NBRV) 12.86% +0.68, Great Panther Silver (GPL) 13.59% +0.62, Ark Fintech Innovation (ARKF) 3.05% +0.39, Pluristem (PSTI) 32.66% +0.27, AppHarvest (APPH) 24.93% +0.25, CC Neuberger Principal Holdings II (PRPB) 0.48% +0.23, Navios Maritime Partners (NMM) 4.71% +0.20, and Clover Health (CLOV) 2.39% +0.17.
|Over a month ago|
Clover Health initiated with a Neutral at Credit Suisse » 06:1003/0903/09/21
Credit Suisse analyst…
Credit Suisse analyst Jailendra Singh initiated coverage of Clover Health with a Neutral rating and $10 price target. While Singh sees a long runway of growth in the fast-growing Medicare Advantage industry, the analyst notes that concerns around disclosures and marketing practices raised by a recent short seller report, as well as broader market volatility around high-growth names, have led to significant volatility in shares recently. While management's response to the short seller report is reassuring, Singh believes it could take some time for the sentiment to improve, the analyst tells investors in a research note.
Clover Health, Mass. General secure grant from National Institute of Health » 16:4603/0403/04/21
Clover Health Investments…
Clover Health Investments announced it is part of a team that received a five-year grant from the National Institutes of Health to conduct a clinical study with researchers from Massachusetts General Hospital, Harvard Medical School and ACP Decisions, a non-profit foundation focused on advanced care planning. The study focuses on the effectiveness of multimedia tools for improving advance care planning among patients with life-limiting illness receiving home-based primary care. The number of patients living with serious chronic illness and receiving home-based care through house call providers is increasing. Often, these patients lack exposure to specialty palliative care and receive education and counseling on advance care planning much too late. Healthcare systems are seeking scalable solutions that provide advance care planning services to more patients earlier in their disease course yet are constrained by the scarcity of palliative care clinicians and the lack of clinical programs outside the hospital setting. The goal of the study is to understand the effectiveness of using video-based advance care planning resources to optimize serious illness medical care for patients with chronic, life-limiting illnesses receiving home-based care. The innovative approach will incorporate predictive analytics and video technology to significantly expand access to advance care planning for a highly vulnerable population of patients.
Clover Health price target lowered to $13 from $19 at Citi » 06:4703/0303/03/21
Citi analyst Ralph…
Citi analyst Ralph Giacobbe lowered the firm's price target on Clover Health Investments to $13 from $19 and keeps a Buy rating on the shares post the Q4 results. The analyst acknowledges the "difficult start out of the gates" with results that fell shy of expectations, and a short report "that has created an overhang." That said, he believes it is "premature to throw in the towel," and remains optimistic around Clover Health's direct contracting opportunity.